Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial - PubMed
3 hours ago
- #endometrial cancer
- #immunotherapy
- #clinical trial
- Dostarlimab plus carboplatin-paclitaxel chemotherapy showed sustained progression-free survival and overall survival benefits in dMMR/MSI-H advanced or recurrent endometrial cancer after about 4 years of follow-up in the RUBY trial.
- The risk of death was reduced by 66% compared to chemotherapy alone, with progression-free survival curve plateauing, indicating durable disease control.
- A mixture cure model estimated a 54% cure rate with dostarlimab plus chemotherapy at 4 years, suggesting potential for curative intent.
- Conditional survival analyses indicated that patients alive at 1 and 2 years had over 80% probability of surviving an additional 3 and 2 years, respectively.
- No new safety signals were observed, and the treatment regimen was well-tolerated over the extended follow-up period.